Jan 16

T3 Pharma research project receives support by the Gebert Rüf Stiftung

Basel/Switzerland, January 16, 2017 – The Gebert Rüf Stiftung has announced the winners of the call 2016 «Microbials – Direct Use of Micro-Organisms». Amongst the supported projects is T3 Pharma’s innovative bacteria-based cancer therapy. The applied research project takes place at the University of Basel, the results will allow T3 Pharma to expand its activities in the field of cancer treatment using live bacteria.

With the call «Microbials – Direct Use of Micro-Organisms», held for the first time, the Gebert Rüf Stiftung seeks to jumpstart the direct use of modified or domesticated micro-organisms in human and veterinary medicine as well as other areas. Out of 54 submissions 5 projects were selected for funding. «Microbial Treatment of Solid Tumors», a collaborative effort between the Biozentrum and the Department Biomedicine of the University of Basel and T3 Pharma, is amongst the selected projects and will receive CHF 400’000 in the next two years.

“Our bacteria-based therapies hold great potential for the treatment of solid tumors and it is our aim to broadly exploit this innovative platform”, said Dr. Simon Ittig, CEO of T3 Pharma. “We are very pleased that the Gebert Rüf Stiftung shares this vision and are convinced that its support will help to significantly advance the project.”

For further information, contact
Dr. Simon Ittig, CEO
Phone: +41 61 207 20 74
Email: s.ittig@t3pharma.com

About T3 Pharma
The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-off of the University of Basel. T3 Pharma is developing an efficient protein delivery technology that is based on the use of live bacteria expressing the type 3 secretion system. While the technology has a wide spectrum of applications in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach to treat solid tumors.

About Gebert Rüf Stiftung
Gebert Rüf Stiftung was established as a scientific foundation in 1997 by the entrepreneur Heinrich Gebert. The purpose of the Foundation is to strengthen Switzerland as a business location and place to live in through the promotion of scientific projects at Swiss institutions of higher education. These can be projects in all disciplines, provided they exhibit a high degree of originality, foster intellectual and practical stimulus and thus promise to be of material or immaterial benefit to society. As a private foundation with limited funds, Gebert Rüf Stiftung strives to occupy scientific niches and fill structural and procedural gaps in the world of research. For further information, please visit www.grstiftung.ch.

Nov 23

T3 Pharma closes first financing round to advance research and preclinical development of breakthrough bacteria-based cancer therapies

Basel/Switzerland, November 23, 2016 – T3 Pharmaceuticals Ltd (“T3 Pharma”), a Swiss-based biotechnology company specializing in breakthrough bacteria–based cancer therapies, today announced the successful closing of its first financing round. The funding has been provided by private Swiss investors and will secure further growth of the company, in particular the expansion of research activities and the initiation of preclinical development.

The financing round complements the successful efforts raising significant non-dilutive capital from the Swiss Commission for Technology and Innovation and various research foundations. T3 Pharma is a spin-off from the Biozentrum of the University of Basel. The Company focuses on novel therapies for cancer patients. T3 Pharma has been engineering live bacteria to specifically infect solid tumors and fighting them with a proprietary protein delivery technology developed at the University of Basel.

“Our strong investor base and the support by the University of Basel provide perfect conditions for the development of our breakthrough technology in cancer therapies”, said Dr. Simon Ittig, CEO and  co-founder of T3 Pharma. “This first financing round allows us to advance initial lead candidates into preclinical development.”

“It belongs to the mission of a modern University to help translating basic research into tangible benefits for patients and society,” explained Prof. Dr. Erich Nigg, Director of the Biozentrum. “We hope that T3 Pharma can exploit their innovative platform to bring novel treatments to cancer patients.”

For further information, contact
Dr. Simon Ittig, CEO
Phone: +41 61 267 20 74
Email: s.ittig@t3pharma.com

About T3 Pharma
The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-off of the University of Basel. T3 Pharma is developing an efficient protein delivery technology that is based on the use of live bacteria expressing the type 3 secretion system. While the technology has a wide spectrum of applications in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach to treat solid tumors.

Nov 02

T3 Pharma has been awarded with the CTI startup label

Basel, November 14, 2016 – T3 Pharma has been awarded the CTI Start-up Label by the Commission for Technology and Innovation CTI.

The label is the result of a coaching process that allowed T3 Pharma to refine its corporate strategy. T3 Pharma is honored to have received the Start-up Label which is "a seal of quality, a certificate of achievement, and a sign of credibility and readiness for sustainable growth".

 

 

Jul 01

T3 Pharma wins Venture.ch business plan competition

Basel/Switzerland, July 1, 2016 – We are happy to announce that T3 Pharma has won the venture.ch business plan competition. It’s a big honor and without the many people that support us it would not have been possible.

Thank you all!

The T3 Pharma Team

(Image: Venture 2016)

Our mission


T3 Pharmaceuticals is a pre-clinical biopharmaceutical company working to advance new generation therapies for cancer patients. Our dedicated team is developing highly specific and efficient treatments using live bacteria.
  • |